絞り込み

16546

広告

Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer.

著者 Wang H , Zeng C , Li X , Wang Y , Li X , Ge W
Future Oncol.2018 Oct 15 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (21view , 0users)

Full Text Sources

Miscellaneous

To evaluate the cost-utility of gefitinib and afatinib as first-line EGFR-mutated non-small-cell lung cancer treatments from the Chinese healthcare system perspective.
PMID: 30320506 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード